A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV.

Trial Profile

A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Kaposi's sarcoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 04 May 2017 Planned End Date changed from 30 Jun 2018 to 31 Dec 2017.
    • 20 Jan 2017 Planned End Date changed from 1 Jun 2018 to 30 Jun 2018.
    • 01 Dec 2016 Results assessing safety, pharmacokinetics and efficacy of Pomalidomide (n= 22) published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top